Clinical trials: Binge Eating Disorder (BED)
Binge Eating Disorder
Open Label Extension in Adults With Binge Eating Disorder (BED)
To evaluate the safety and tolerability of SPD489 administered as a daily morning dose (50 or 70mg) in the treatment of moderate to severe binge eating disorder (BED) in adults
- Trial name
- NCT01657019
- Testing
- Lisdexamfetamine dimesylate
- Where
- 89 sites in United States, Germany and 1 more
- Volunteers
- 604 people
- Sponsor
- Shire
Binge-Eating Disorder
A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder
This is a Phase 3, multi-center, open-label and randomized withdrawal study to evaluate the long-term safety and efficacy of solriamfetol in the treatment of binge eating disorder (BED) in adults.
- Trial name
- NCT06878976
- Testing
- Solriamfetol
- Where
- 33 sites in United States
- Volunteers
- 236 people
- Sponsor
- Axsome Therapeutics, Inc.
Binge-Eating Disorder
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol…
- Trial name
- ENGAGE (NCT06413433)
- Testing
- Solriamfetol 150 mg, Solriamfetol 300 mg
- Where
- 45 sites in United States
- Volunteers
- 450 people
- Sponsor
- Axsome Therapeutics, Inc.
Attention Deficit Hyperactivity Disorder (ADHD), Binge-Eating Disorder Disorder
Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction
Study of the what the body does to the drug in subjects with mild, moderate, and sever liver dysfunction (not working properly)
- Trial name
- NCT02795637
- Testing
- dasotraline
- Where
- 5 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Sumitomo Pharma America, Inc.